A phase I/Ib study of lenvatinib and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Lara Dunn,Alan Loh Ho,Juliana Eng,Loren S. Michel,James Vincent Fetten,Elizabeth Warner,Anuja Kriplani,Wanqing Iris Zhi,Kenneth K. Ng,Sofia Haque,David G. Pfister,Eric J. Sherman

A phase I/Ib study of lenvatinib and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

2020

Lara Dunn
Alan Loh Ho
Juliana Eng
Loren S. Michel
James Vincent Fetten
Elizabeth Warner
Anuja Kriplani
Wanqing Iris Zhi
Kenneth K. Ng
Sofia Haque
David G. Pfister
Eric J. Sherman

6541Background: Despite overexpression of EGFR in HNSCC, cetuximab monotherapy has limited benefit. Fibroblast growth factor receptor (FGFR) signaling is a known resistance mechanism to EGFR inhibi...

Keywords:

Oncology
in patient
Lenvatinib
Cetuximab
Pathology
Head and neck squamous-cell carcinoma
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations